Recent outbreaks of hantavirus, including cases aboard a 2026 cruise ship, have prompted renewed preclinical research into mRNA and DNA vaccine candidates targeting strains such as Andes and Hantaan. However, these efforts remain in early stages: no candidate has advanced beyond small Phase 1 human trials or rodent testing, where neutralizing antibodies were induced but required multiple doses. Standard regulatory timelines for completing Phase 2 and 3 trials, followed by FDA review, extend well beyond 2026 absent an unprecedented acceleration comparable to Operation Warp Speed. Trader consensus at 91.5% implied probability for no approval reflects this pipeline reality, though a sudden major funding infusion or breakthrough data release could introduce limited upside risk.